PROF:NASDAQProfound Medical Corp. Analysis

PROF is trading at $6.99, comfortably above its 20‑day ($6.51), 50‑day ($6.40) and 200‑day ($6.17) simple moving averages, with a bullish MACD crossover (0.18 vs signal 0.11) and an RSI of 58.7 indicating modest upward momentum. The stock sits near a support level of $5.84 and faces resistance around $7.23, while recent volume has tapered, suggesting a quieter market environment ahead. Revenue surged 43% year‑over‑year to $16.1 M and gross margins remain strong at 71%, but operating and net margins are still negative, and EBITDA is a deep loss of $40.7 M, reflecting a company in a growth‑investment phase. Cash balances of $59.7 M comfortably exceed debt of $4.7 M, providing a solid runway despite a high debt‑to‑equity ratio of 7.1. Analyst consensus targets a median price of $12, implying roughly 70% upside, and the market sentiment index reads “Extreme Greed” at 88, underscoring strong investor enthusiasm. Recent material news includes PROF’s participation in the Bloom Burton & Co. Healthcare Investor Conference and multiple presentations of its TULSA‑PRO system at the Society of Interventional Radiology, which should raise visibility and potentially accelerate adoption. While volatility is elevated (30‑day ≈ 76%) and beta is above 1 in the computed data, the company’s niche in AI‑driven, MRI‑guided, incision‑free therapies offers a compelling long‑term growth narrative in the medical‑device sector.